Browse Studies — Arctuva

Phase 2

A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant …

Acral Lentiginous MelanomaClinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Cutaneous Melanoma+4 more

Estimated

~$10 – $7,500

SWOG Cancer Research NetworkNCT04511013

Phase 1

PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer, Pre-Treated Nonsmall Cell Lung Cancer and PD1/PD-L1 Inhibitor-Refractory Melanoma

This phase I trial studies the safety of personalized neo-antigen peptide vaccine in treating patients with stage IIIC-IV melanoma, hormone receptor positive H…

Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Locally Advanced Cutaneous Melanoma+22 more

Estimated

Phase 2

The TIME Trial - Phase II Randomized Controlled Trial of Time-of-Day Specified Immunotherapy for Advanced Melanoma

This phase II trial tests the safety and effectiveness of giving ipilimumab and nivolumab in the morning compared to other times of day in treating patients wi…

Advanced Acral MelanomaAdvanced Cutaneous MelanomaAdvanced Mucosal Melanoma+7 more

Estimated

~$10 – $6,250

Emory UniversityNCT07155317